Ovarian Cancer

Primary Cytoreductive Surgery Associated With Improved Survival in Ovarian Cancer

Primary Cytoreductive Surgery Associated With Improved Survival in Ovarian Cancer

By

The benefits of primary cytoreductive surgery relative to neoadjuvant chemotherapy remain uncertain; therefore, researchers performed a retrospective data analysis to compare overall survival of surgery with that of neoadjuvant chemotherapy in advanced-stage epithelial ovarian cancer.

Neoadjuvant Chemotherapy Use on the Rise in Ovarian Cancer Treatment

Neoadjuvant Chemotherapy Use on the Rise in Ovarian Cancer Treatment

NeoadjuvantcChemotherapy (NACT) use went up from 2003 to 2012; linked to shorter overall survival in stage IIIC but not stage IV disease.

Chemotherapy During Pregnancy May Limit Baby's Fertility in Girls

Chemotherapy During Pregnancy May Limit Baby's Fertility in Girls

By

Etoposide was found to damage ovarian tissue in the developing fetus in a study evaluating the effect of the drug on mouse ovarian tissue grown in vitro.

Novel Pathway Improves Access to Genetic Testing for Women With Ovarian Cancer

Novel Pathway Improves Access to Genetic Testing for Women With Ovarian Cancer

By

Rapid, robust, and affordable genetic testing for patients with ovarian cancer that allows a much larger portion of patients to benefit from personalized cancer management and their relatives to benefit from preventive strategies can be achieved.

Socioeconomic Status Inversely Related to Risk for Ovarian Cancer in African American Women

By

Risk of ovarian cancer is higher in African American women with lower socioeconomic status, the opposite of trends seen in breast cancer.

Imaging and Fluorescence Technique Guides Surgical Removal of Otherwise Undetectable Ovarian Tumors

By

A newly created tumor-specific fluorescent molecule combined with an imaging system guided surgeons to removing additional tumors not palpable or visible without fluorescence in patients with ovarian cancer.

Chemotherapy Boosts Effectiveness of Immunotherapy in the Treatment of Ovarian Cancer

Chemotherapy Boosts Effectiveness of Immunotherapy in the Treatment of Ovarian Cancer

By

Immunotherapy for advanced ovarian cancer more effectively treats tumors when administered immediately after chemotherapy. Sequential chemoimmunotherapy could improve disease control in stage IIIC/IV tubo-ovarian HGSC.

Exercise May Protect Against Epithelial Ovarian Cancer

Exercise May Protect Against Epithelial Ovarian Cancer

Chronic inactivity has been linked to greater risk for ovarian cancer.

Number of Ovarian Cancer Cases Not Treated Surgically or Not Treated at All Is Increasing

Number of Ovarian Cancer Cases Not Treated Surgically or Not Treated at All Is Increasing

By

The number of patients older than 75 years who do not undergo surgery is increasing, especially among those with stage III or IV ovarian cancer. Approximately 50% do not undergo surgery and 25% receive no treatment at all.

Genetic Subtypes of HLA Are Linked to Increased Overall Risk of Ovarian Cancer

By

Overall risk of developing ovarian cancer may be higher for women with certain types of human leukocyte antigen (HLA), which could underlie differences in their response to immunotherapy.

Cell Changes in Fallopian Tubes of BRCA Mutation Carriers May Lead to Strategies for Preventing Ovarian Cancer

By

Recognition of early changes in the Fallopian tube cells of BRCA gene mutation carriers may be key to new strategies for preventing ovarian cancer that could also reduce the need for invasive surgery.

Study Finds Racial Disparities in Breast and Ovarian Cancer Risk Management

Study Finds Racial Disparities in Breast and Ovarian Cancer Risk Management

By

Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors underscores that "the benefit from genetic testing comes from acting on the test results," not just the testing itself, a study presented at the ASCO 2016 Annual Meeting concluded.

T Cells Have the Potential to Reverse Chemotherapy Resistance in Patients With Ovarian Cancer

By

A new perspective on chemotherapy resistance in ovarian cancer may be a step toward overcoming that resistance. Fibroblasts block chemotherapy, leading to chemotherapy resistance; however, immune system T cells can reverse that resistance.

No Clinical Benefit to Expanding Gene Panel Beyond Ovarian and Breast Cancer Genes in High-risk Women

By

Expanding a panel of tested genes beyond the known breast and ovarian cancer-specific genes in patients with breast and ovarian cancer did not confer any clinical benefit.

Obesity Can Mask Ovarian Cancer Symptoms in African American Women

By

Excess abdominal fat in overweight and obese women could interfere with detection of early symptoms of ovarian cancer, and this may contribute to the higher risk of death from ovarian cancer in African American women compared with white women.

Effect of Childbirth on Risk of Ovarian Cancer Diminishes With Age, But Effect of Oral Contraceptive Use Is Constant

Effect of Childbirth on Risk of Ovarian Cancer Diminishes With Age, But Effect of Oral Contraceptive Use Is Constant

By

Prior oral contraceptive use is associated with reduced risk for ovarian cancer among women of all ages; however, risk reductions associated with childbirth wane as women age

Optimal Tumor Reduction, Platinum Sensitivity Characterize Long-term Ovarian Cancer Survival

Optimal Tumor Reduction, Platinum Sensitivity Characterize Long-term Ovarian Cancer Survival

By

Women who are long-term survivors of high-grade serous carcinoma (HGSC) usually have platinum-sensitive disease.

Mastectomy Increases Life Expectancy in Younger Women With Ovarian Cancer

By

Risk-reducing mastectomy (RRM) can increase life expectancy and be cost effective in women up to age 60 years with ovarian cancer as carriers of a BRCA mutation.

Patient-reported Outcomes Show Tamoxifen Plus OFS Worse

Patient-reported Outcomes Show Tamoxifen Plus OFS Worse

By

Women who received tamoxifen plus ovarian function suppression (OFS) reported worse endocrine symptoms and sexual functioning.

Hormone Replacement Therapy Improves Bone Mineral Loss After Salpingo-oophorectomy for Ovarian Cancer

By

In patients who undergo risk-reducing salpingo-oophorectomy, BMD screenings are underutilized in spite of the prevalence of bone mineral loss in this population. Hormone replacement therapy can address BMD loss in these women.

Progression-free and Overall Survival Better With Mutations Affecting DNA Repair Genes in Ovarian Cancer

By

Women with advanced ovarian cancer who had mutations affecting DNA repair genes had longer progression-free and overall survival than women without the mutations.

Current Use of Antihypertensives Linked With Slight Increase in Ovarian Cancer Risk

Current Use of Antihypertensives Linked With Slight Increase in Ovarian Cancer Risk

By

Current use of antihypertensive medication may be associated with a slightly increased risk for ovarian cancer.

Farletuzumab Fails to Improve Survival in Ovarian Cancer

Farletuzumab Fails to Improve Survival in Ovarian Cancer

By

Adding farletuzumab to carboplatin and a taxane failed to improve progression-free survival in patients with platinum-sensitive ovarian cancer.

Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role?

Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role?

[Journal of Gastrointestinal Oncology] This research examines the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of ovarian cancer.

Ovarian Cancer Includes More Than One Kind of Malignancy

Ovarian Cancer Includes More Than One Kind of Malignancy

Ovarian cancer isn't a single disease, but rather a number of different malignancies, and better understanding is needed to improve prevention and treatment according to a U.S. panel.

Weekly Paclitaxel Doesn't Increase Survival in Ovarian Cancer

Weekly Paclitaxel Doesn't Increase Survival in Ovarian Cancer

Paclitaxel administered with carboplatin on a weekly basis is not associated with improved progression-free survival.

Nine Additional Inherited Gene Mutations Are Linked to Ovarian Cancer

Nine Additional Inherited Gene Mutations Are Linked to Ovarian Cancer

By

Among 1915 patients with ovarian cancer, almost 1 in 5 had inherited mutations in genes associated with risk of ovarian cancer. Furthermore, a total of 11 genes are now suspected of causing hereditary ovarian cancer.

Additional Genes Linked With Ovarian Cancer Risk Identified

By

The researchers found that nearly one fifth of women with ovarian cancer carried mutations in genes that were associated with ovarian cancer risk beyond the BRCA1 and BRCA2 genes.

Risk of Ovarian Cancer Predicted With Fine-tuned Test

By

A recent study fine-tuned the popular Simple Rules ultrasound test for ovarian cancer.

Better Approaches to Patient Counseling of BRCA Gene Mutation Carriers Needed

Better Approaches to Patient Counseling of BRCA Gene Mutation Carriers Needed

By

An in-depth look at the issues associated with the care reveals a need to improve how clinicians can help these women sort through their options.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs